UGT1A1 and Hyperbilirubinemia: We examined two well-known genetic polymorphisms of UGT1A1*28 and MDR1 2677 related to atazanavir-induced hyperbilirubinemia [14], but failed to demonstrate statistically significant correlation between the genetic polymorphisms and incident cholelithiasis and nephrolithiasis.